Remedy: Patience will be rewarded

By Atte Riikola
Remedy's Q1 result was stronger than we had expected, but the main thing was that the 5 major game projects under development are progressing as planned. According to our estimates, these projects will become more clearly visible in Remedy's earnings growth only in 2024-2025, which means that some patience from investors is required. With our estimates, the share’s valuation becomes so low at that point that we consider the return/risk ratio very attractive for investors who play the long game.